Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Pfiz­er is plan­ning to leave the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion, a source fa­mil­iar with the mat­ter con­firmed to End­points News, as it will not re­new its mem­ber­ship when it laps­es.

Pfiz­er and BIO did not re­turn re­quests for com­ment. But the com­pa­ny’s move comes as it em­barks on a multi­bil­lion-dol­lar cost-cut­ting plan af­ter tak­ing a ma­jor rev­enue re­duc­tion due to its Covid prod­ucts this year, with re­duced de­mand over the longer term. Pfiz­er’s de­par­ture plans from BIO were re­port­ed ear­li­er by STAT.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.